Endocrinology, Vol 128, 1285-1290, Copyright © 1991 by Endocrine Society

ARTICLES

Effect of relaxin on mammary development in ovariectomized pregnant gilts

WL Hurley, RM Doane, MB O'Day-Bowman, RJ Winn, LE Mojonnier and OD Sherwood
Department of Animal Sciences, University of Illinois, Urbana 61801.

The role of relaxin in mammary development was studied between days 80- 110 of pregnancy in ovariectomized gilts given progesterone to maintain pregnancy. To obtain an objective measurement of lobulo-alveolar (parenchymal) composition, mammary glands were cut in cross-section through the teat, and the area of parenchymal tissue on the exposed face of the gland was determined. Ovariectomy on day 80 or 100 followed by progesterone replacement therapy resulted in a dramatic reduction in the rate of growth of mammary parenchymal cross-section area on days 100 and 110 of gestation, respectively, compared to that in controls. In contrast, progesterone plus relaxin therapy, with highly purified porcine relaxin, restored the mammary parenchymal cross-section area to control values in ovariectomized gilts. Morphometric analysis of mammary tissue on day 110 of pregnancy indicated that both the absence of relaxin after ovariectomy and replacement therapy with porcine relaxin in ovariectomized gilts had little if any effect on the percentages of the lumen, stroma, or epithelial that comprised the mammary parenchyma. It is concluded that relaxin has a stimulatory effect on the growth of mammary parenchymal tissue during late gestation in the pig.

This article has been cited by other articles:

				W. Yan, A. A. Wiley, R. A. D. Bathgate, A.-L. Frankshun, S. Lasano, B. D. Crean, B. G. Steinetz, C. A. Bagnell, and F. F. Bartol Expression of LGR7 and LGR8 by Neonatal Porcine Uterine Tissues and Transmission of Milk-Borne Relaxin into the Neonatal Circulation by Suckling Endocrinology, September 1, 2006; 147(9): 4303 - 4310. [Abstract] [Full Text] [PDF]

				F. Ji, W. L. Hurley, and S. W. Kim Characterization of mammary gland development in pregnant gilts J Anim Sci, March 1, 2006; 84(3): 579 - 587. [Abstract] [Full Text] [PDF]

				A. A. Kamat, S. Feng, N. V. Bogatcheva, A. Truong, C. E. Bishop, and A. I. Agoulnik Genetic Targeting of Relaxin and Insulin-Like Factor 3 Receptors in Mice Endocrinology, October 1, 2004; 145(10): 4712 - 4720. [Abstract] [Full Text] [PDF]

				O. D. Sherwood Relaxin's Physiological Roles and Other Diverse Actions Endocr. Rev., April 1, 2004; 25(2): 205 - 234. [Abstract] [Full Text] [PDF]

				S. Zhao, P. A. Fields, and O. D. Sherwood Evidence That Relaxin Inhibits Apoptosis in the Cervix and the Vagina during the Second Half of Pregnancy in the Rat Endocrinology, June 1, 2001; 142(6): 2221 - 2229. [Abstract] [Full Text] [PDF]

				E. N. Unemori, M. E. Erikson, S. E. Rocco, K. M. Sutherland, D. A. Parsell, J. Mak, and B. H. Grove Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women Hum. Reprod., March 1, 1999; 14(3): 800 - 806. [Abstract] [Full Text] [PDF]

				T. Kohsaka,, G. Min,, G. Lukas,, S. Trupin,, E. T. Campbell,, and O. D. Sherwood Identification of Specific Relaxin-Binding Cells in the Human Female Biol Reprod, October 1, 1998; 59(4): 991 - 999. [Abstract] [Full Text]

				G. Min, M. G. Hartzog, R. L. Jennings, R. J. Winn, and O. D. Sherwood Evidence That Endogenous Relaxin Promotes Growth of the Vagina and Uterus during Pregnancy in Gilts Endocrinology, February 1, 1997; 138(2): 560 - 565. [Abstract] [Full Text] [PDF]